Cargando…

Synthetic cannabinoids

Use of cannabinoids is increasing at an alarming rate. Their easy availability, cheapness, perceptive legality and difficulty in detecting its presence with standard urine toxicologic tests, and similar factors probably contribute to the increased use, and popularity of synthetic cannabinoids. Altho...

Descripción completa

Detalles Bibliográficos
Autor principal: Bilici, Rabia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kare Publishing 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175064/
https://www.ncbi.nlm.nih.gov/pubmed/28058316
http://dx.doi.org/10.14744/nci.2014.44153
_version_ 1782484587138514944
author Bilici, Rabia
author_facet Bilici, Rabia
author_sort Bilici, Rabia
collection PubMed
description Use of cannabinoids is increasing at an alarming rate. Their easy availability, cheapness, perceptive legality and difficulty in detecting its presence with standard urine toxicologic tests, and similar factors probably contribute to the increased use, and popularity of synthetic cannabinoids. Although laws, and regulations concerning auditing of these substances have been implemented in many countries, production of new types of synthetic cannabinoids rapidly takes place. Primary psychoactive ingredient of cannabis is Δ 9-tetrahydrocannabinoid which is partial agonist of cannabinoid receptors, while synthetic cannabinoids are potent, and complete agonists of these receptors. Therefore it is not surprising that synthetic cannabinoids exert more powerful effects than cannabinoids. Clinical effects of synthetic cannabinoids can cause referrals to emergency services, and hospitalizations. Despite lack of any specific therapy benzodiazepines, antipsychotics, and fluid replacement may be required. Clinical follow-up studies are needed for better comprehension of its clinical effects, and treatment outcomes.
format Online
Article
Text
id pubmed-5175064
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kare Publishing
record_format MEDLINE/PubMed
spelling pubmed-51750642017-01-05 Synthetic cannabinoids Bilici, Rabia North Clin Istanb Review Use of cannabinoids is increasing at an alarming rate. Their easy availability, cheapness, perceptive legality and difficulty in detecting its presence with standard urine toxicologic tests, and similar factors probably contribute to the increased use, and popularity of synthetic cannabinoids. Although laws, and regulations concerning auditing of these substances have been implemented in many countries, production of new types of synthetic cannabinoids rapidly takes place. Primary psychoactive ingredient of cannabis is Δ 9-tetrahydrocannabinoid which is partial agonist of cannabinoid receptors, while synthetic cannabinoids are potent, and complete agonists of these receptors. Therefore it is not surprising that synthetic cannabinoids exert more powerful effects than cannabinoids. Clinical effects of synthetic cannabinoids can cause referrals to emergency services, and hospitalizations. Despite lack of any specific therapy benzodiazepines, antipsychotics, and fluid replacement may be required. Clinical follow-up studies are needed for better comprehension of its clinical effects, and treatment outcomes. Kare Publishing 2014-12-08 /pmc/articles/PMC5175064/ /pubmed/28058316 http://dx.doi.org/10.14744/nci.2014.44153 Text en Copyright: © Istanbul Northern Anatolian Association of Public Hospitals http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Review
Bilici, Rabia
Synthetic cannabinoids
title Synthetic cannabinoids
title_full Synthetic cannabinoids
title_fullStr Synthetic cannabinoids
title_full_unstemmed Synthetic cannabinoids
title_short Synthetic cannabinoids
title_sort synthetic cannabinoids
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5175064/
https://www.ncbi.nlm.nih.gov/pubmed/28058316
http://dx.doi.org/10.14744/nci.2014.44153
work_keys_str_mv AT bilicirabia syntheticcannabinoids